Pioneering 3D Human Tissues for Drug Discovery

May 21 | 2024

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

Read More »

May 14 | 2024

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Read More »

May 08 | 2024

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Read More »